®Reading a message, checking a menu and looking up to join a conversation should feel like connected parts of the day. Yolia Health’s True Vision Treatment, or TVT, brings a distinctive approach to presbyopia: customized corneal optics delivered through a defined, nonsurgical treatment course.
TVT combines individually designed gas-permeable contact lenses with ophthalmic formulations. Its value proposition is clear: personalize the treatment to the eye and support useful near vision after the treatment lenses are removed. [2]
A defined treatment course, followed by useful vision
TVT separates the treatment period from the period in which patients experience the optical benefit. A published account of the Aguascalientes study describes near-vision improvement during six months of follow-up after a seven-day regimen in 50 adults. [2]
For patients interested in reducing dependence on a daily near-vision treatment routine, that is a meaningful feature. A prescribed course creates a different rhythm of care, with lens fitting, treatment and professional follow-up organized around the individual response.
Duration and retreatment needs vary. The practical advantage lies in the course-based approach and the observed benefit after that course, rather than a promise of permanent correction.
Personalized optics based on the individual eye
TVT uses corneal measurements to guide the custom lens design. The Aguascalientes account describes topographic changes consistent with a multifocal corneal effect, alongside improved near vision and no apparent loss of distance acuity in the reported study. [2]
This gives personalization a concrete role in treatment. The clinician measures the eye, fits the lens and follows the response. The aim is useful vision that supports the patient’s own activities, from reading print to shifting attention across the room.
TVT’s proposed mechanism centers on corneal optical change. That distinguishes it from presbyopia drops that use pharmacological pupil constriction to increase depth of focus. The distinction creates a clear choice in how near-vision care can be delivered.
Nonsurgical treatment with a practical patient focus
TVT’s lens-and-formulation approach offers a nonsurgical path for people seeking personalized presbyopia care. It brings together custom fitting and a defined treatment period, with ongoing professional assessment.
The consultation can focus on the activities the patient values: reading instructions, using a phone, working at a screen or enjoying a meal without repeatedly interrupting the moment to manage near vision. These examples describe treatment goals; individual outcomes are assessed during follow-up.
What the new eye-drop study brings into focus
A recent paper by Zuluaga and colleagues examined compounded pilocarpine–diclofenac drops in 741 patients. At one hour, 80.0% reached the authors’ functional near-vision threshold. Temporary dim vision or reduced light perception was reported by 33.1%. The regimen involved repeated daily dosing, and later observations were made during treatment. [1]
The study illustrates why treatment discussions should include both useful vision and the routine required to maintain it. TVT brings a course-based, personalized corneal approach to that discussion.
These are separate studies with different designs and measurements. They do not establish that TVT is more effective or safer than eye drops. The TVT account describes an uncontrolled, company-funded study; the eye-drop study was retrospective and single-center. [1,2]
TVT’s advantage: a personalized approach built around everyday vision
TVT combines three distinctive features: custom corneal optics, nonsurgical treatment and a defined course with reported near-vision benefit during subsequent follow-up. Together, they form a compelling option to discuss with a qualified eye-care professional.
The next step for an interested patient is a personalized assessment: establish the eye’s suitability, define the daily activities that matter and understand the treatment and follow-up available locally.
Discover how Yolia’s personalized TVT approach can fit your near-vision goals.
Sources
[1] Zuluaga AF, Montoya-Giraldo MA, Leiro J, Benozzi G. Presbyopia, Aging, and Modern Near-Vision Demands: Real-World Functional Outcomes of Pilocarpine-Diclofenac Eye Drops. Medicina. 2026;62(11):2113. Published October 30, 2026. Original paper. DOI: 10.3390/medicina62112113.
[2] Rinehart JM, Kenyon KR, Osio A, Monroy JL, Grant S. A New Technology That Improves Near Vision in Presbyopes: Customized Contact Lens Plus Topical Enzyme Treatment. Presbyopia Physician. December 1, 2022;37–39. Published professional account.